Table 2.
Experience using adoptive T-cell therapy for PTLD: third party EBV-CTLs
| Study | Method of selection | Treatment setting | Prior therapy | N | HLA | Response (CR + PR) |
| Alabama Sun et al.[93] Lucas et al.[125] |
EBV-BLCL sensitized EBV-CTL |
PTLD SOT | RT Rituximab/C |
1 1 |
4/6 6/6 |
1/1 (100%) 1/1 (100%) |
| Edinburgh Haque et al.[91] |
EBV-LCL sensitized EBV-CTL | PTLD HCT SOT |
RIS Rituximab/C |
2 31 |
2 - 5/6 2 - 5/6 |
2/2 (100%) 19/31 (61%) |
| Australia Gandhi et al.[92] |
EBV-LCL sensitized EBV-CTL | PTLD SOT | RIS Rituximab/C |
3 | ≥ 3/6 | 2/3 (66%) |
| Baylor Leen et al.[126] |
Transduced multivirus | PTLD HCT | Rituximab | 9 | ≥ 1 | 6/9 (67%) |
| Inserm Gallot et al.[127] |
EBV-LCL sensitized EBV-CTL |
PTLD HCT SOT |
Rituximab/C Rituximab/C |
6 3 |
≥ 2 ≥ 2 |
3/6 (50%) 1/3 (30%) |
| UK Chiou et al.[94] |
EBV-LCL Stimulated EBV-CTL |
PTLD SOT | Rituximab/RIS | 10 | Not specified | 8/10 (80%) |
| Aberdeen Vickers et al.[128] |
EBV-LCL Stimulated EBV-CTL |
PTLD HCT SOT |
N/A N/A |
6 4 |
≥ 3 ≥ 3 |
4/6 (67%) 4/4 (80%) |
| Baylor Tzannou et al.[95] |
Peptide stimulated | PTLD HCT | None | 1 | 3/8 | 1/1 (100%) |
| MSK Prockop et al.[27] |
EBV-LCL sensitized T-cell line |
PTLD HCT SOT |
Rituximab/C Rituximab/C |
33 13 |
2-5/10 2-4/10 |
22/33 (68%) 7/13 (54%) |
| Spain Alonso et al.[129] |
Not specified | PTLD HCT | Not documented | 1 | Not documented | 0/1 (0%) |
PTLD: Post-transplant lymphoproliferative disorder; EBV CTLs: Epstein-Barr virus cytotoxic T cell lines; CR: complete responses; PR: partial response.